Turkar S

432P QTWiST analysis to compare the benefit of maintenance Erlotinib versus pemetrexed patients with EGFR non mutated NSCLC - 2017 -

Background: In an open label, Phase 3 randomised study, Pemetrexed maintenance after induction with 4-6 cycles of pemetrexed -Platinum therapy failed to prove its superiority over Erlotinib in patients with EGFR non mutated NSCLC. In this analysis we have assessed the benefit of erlotinib over Pemetrexed using quality adjusted time without symptom or toxicity analysis method.

Methods: The overall survival in each arm was partitioned into 3 health states. TOX state (Time spent in grade 3 or above toxicity after randomization and before progression), TWiST state (Time spent after randomization before progression without grade 3 or above toxicity) and REL state (Time spent after progression). The mean QTWiST was calculated for each arm using utility coefficients of 0.65 for TOX, 0.71 for TWiST and 0.67 for REL...

non-small-cell lung carcinoma
epidermal growth factor

Powered by Koha